E
ENTBF
vs
S&P 500
S&P 500
Over the past 12 months, ENTBF has outperformed S&P 500, delivering a return of +22% compared to the S&P 500's +18% growth.
Stocks Performance
ENTBF vs S&P 500
Performance Gap
ENTBF vs S&P 500
Performance By Year
ENTBF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Entheon Biomedical Corp
Glance View
Entheon Biomedical Corp. is a biotechnology company, which engages in developing and commercializing dimethyltryptamine based psychedelic therapeutic products. The company is headquartered in Coquitlam, British Columbia. The company went IPO on 2018-05-03. The firm focuses on developing a portfolio of Dimethyltryptamine (DMT) based psychedelic therapeutic products for treating addiction and substance use disorders. The Company’s DMT is advancing and sustaining new models of psychedelic-assisted therapy. The firm is developing a combination of genetic and predictive data analysis to ensure the safest psychedelic treatment possible. The firm is also developing a predictive biomarker response platform in partnership with Divergence NeuroTech. Its biomarker platform is artificial intelligence and machine learning and prescribes suitable psychedelic treatments and provides real-time feedback during a psychedelic event, and informs the development of a post-therapy system of patient-specific support.
